[{"id":"d7a0703a-8b1b-461b-a082-3de4e2b533f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03061188","created_at":"2021-01-17T18:03:06.477Z","updated_at":"2025-02-25T14:37:19.874Z","phase":"Phase 1","brief_title":"Phase I/Ib Study of Nivolumab \u0026 Veliparib in Patients With Advanced Solid Tumors \u0026 Lymphoma","source_id_and_acronym":"NCT03061188","lead_sponsor":"Northwestern University","biomarkers":" BRCA1 • BRCA2 • MSI • POLE • BAP1 • CDK12 • ERCC2 • CHEK2 • RAD51 • FANCA • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • EMSY • FANCD2 • FANCE • PRKDC • FANCC","pipe":" | ","alterations":" MSI-H/dMMR • RAD50 mutation","tags":["BRCA1 • BRCA2 • MSI • POLE • BAP1 • CDK12 • ERCC2 • CHEK2 • RAD51 • FANCA • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • EMSY • FANCD2 • FANCE • PRKDC • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAD50 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 05/23/2017","start_date":" 05/23/2017","primary_txt":" Primary completion: 03/11/2018","primary_completion_date":" 03/11/2018","study_txt":" Completion: 08/04/2020","study_completion_date":" 08/04/2020","last_update_posted":"2024-06-12"},{"id":"04495210-d346-4ec0-a195-5cf3933896b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05038839","created_at":"2021-09-09T13:53:06.097Z","updated_at":"2024-07-02T16:35:09.419Z","phase":"Phase 1","brief_title":"Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors","source_id_and_acronym":"NCT05038839","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD50 • PARP1 • CHEK1 • EMSY","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • RAD50 mutation • CHEK1 mutation • CHEK1 expression","tags":["BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD50 • PARP1 • CHEK1 • EMSY"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • RAD50 mutation • CHEK1 mutation • CHEK1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Partruvix (pamiparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/09/2022","start_date":" 02/09/2022","primary_txt":" Primary completion: 06/03/2024","primary_completion_date":" 06/03/2024","study_txt":" Completion: 06/03/2024","study_completion_date":" 06/03/2024","last_update_posted":"2024-04-16"},{"id":"731ab927-ac32-42ee-9011-baa1124b987d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05229588","created_at":"2022-02-12T17:48:13.004Z","updated_at":"2024-07-02T16:35:21.201Z","phase":"Phase 2","brief_title":"Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations","source_id_and_acronym":"NCT05229588","lead_sponsor":"HonorHealth Research Institute","biomarkers":" BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD51 • BRIP1 • NBN • EMSY","pipe":" | ","alterations":" BRCA1 mutation • ATM mutation • PTEN mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • NBN mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD51 • BRIP1 • NBN • EMSY"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • ATM mutation • PTEN mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • NBN mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-02-02"},{"id":"5c9cf0d2-4000-4d44-8b92-7009c77ded0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04187833","created_at":"2021-01-18T14:26:39.615Z","updated_at":"2024-07-02T16:35:28.977Z","phase":"Phase 2","brief_title":"Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes","source_id_and_acronym":"NCT04187833","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" TMB • BRCA1 • BRCA2 • BAP1 • MLH1 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD50 • PARP1 • CHEK1 • NBN • HDAC2 • EMSY • ERCC3 • PRKDC • LIG3","pipe":"","alterations":" ","tags":["TMB • BRCA1 • BRCA2 • BAP1 • MLH1 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD50 • PARP1 • CHEK1 • NBN • HDAC2 • EMSY • ERCC3 • PRKDC • LIG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Talzenna (talazoparib)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 06/05/2020","start_date":" 06/05/2020","primary_txt":" Primary completion: 10/13/2023","primary_completion_date":" 10/13/2023","study_txt":" Completion: 10/13/2023","study_completion_date":" 10/13/2023","last_update_posted":"2023-11-16"},{"id":"ff7c1831-8767-420c-a63e-fc4a8e3a8271","acronym":"","url":"https://clinicaltrials.gov/study/NCT04042831","created_at":"2021-01-18T19:49:54.652Z","updated_at":"2024-07-02T16:35:33.579Z","phase":"Phase 2","brief_title":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations","source_id_and_acronym":"NCT04042831","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" BRCA1 • BRCA2 • PTEN • ARID1A • BRCA • CHEK2 • RAD51 • ATR • BRIP1 • NBN • EMSY","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • PTEN mutation • ARID1A mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • BRCA mutation • NBN mutation • EMSY mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • PTEN • ARID1A • BRCA • CHEK2 • RAD51 • ATR • BRIP1 • NBN • EMSY"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • PTEN mutation • ARID1A mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • BRCA mutation • NBN mutation • EMSY mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/24/2020","start_date":" 06/24/2020","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2023-10-13"},{"id":"d89f661a-9bfa-4241-9419-4ddb9238c7df","acronym":"","url":"https://clinicaltrials.gov/study/NCT04895046","created_at":"2021-05-20T11:54:00.267Z","updated_at":"2025-02-25T13:12:38.960Z","phase":"Phase 2","brief_title":"Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma","source_id_and_acronym":"NCT04895046","lead_sponsor":"Walid Shaib, MD","biomarkers":" BRCA1 • BRCA2 • PTEN • ARID1A • BAP1 • CHEK2 • RAD51 • BRIP1 • CHEK1 • BARD1 • NBN • FANCM • EMSY • RPA1","pipe":" | ","alterations":" HRD signature","tags":["BRCA1 • BRCA2 • PTEN • ARID1A • BAP1 • CHEK2 • RAD51 • BRIP1 • CHEK1 • BARD1 • NBN • FANCM • EMSY • RPA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD signature"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/11/2021","start_date":" 10/11/2021","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2022-06-29"}]